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Summary A novel anti-tumour amphibian oocyte RNase, ONCONASER (ONC), previously known as P-30
Protein, is in the clinical trials. The effect of ONC alone and in combination with lovastatin (LVT), an
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of
mevalonate (MVA) and cholesterol synthesis pathway, in three human tumour cell lines ASPC-1 pancreatic,
A-549 lung, and HT-520 lung carcinomas, has been presently studied. A synergism between ONC and LVT in
inducing the cytostatic and cytotoxic effects was observed. The cytostatic effect, seen during the early phase of
the treatment with this combination of drugs was manifested as prolongation of the cell cycle duration,
especially of the GI phase; cell death was apparent after 72 h of treatment. The synergistic effect of ONC and
LVT was also evident in the clonogenicity assays. Both LVT lactone and its in vitro activated beta-hydroxy
acid form, alone and in respective combinations with ONC, exerted similar degree of growth suppression. The
effects of both forms of LVT (used alone or in combination with ONC) were reversed by MVA, which
suggests that HMG-CoA reductase inhibition is a primary mechanism of LVT action. The data indicate that
the LVT lactone can be activated intracellularly by tumour cells studied, and that the combination of ONC
with LVT can produce significantly enhanced anti-tumour activities.
Several years ago interesting observations were made that the
malignant cell growth could be brought under control by the
embryonic environment (Mintz & Illmensee, 1975; Papaioan-
nou et al., 1975). Introduction of tumour cells into the early
mouse embryo resulted in development of a chimeric form in
which a proportion of tumour cells was diminished compared
to the normal cells when transplanted into the embryo. This
suggested some embryonic regulatory mechanism, affecting
tumour cell growth and differentiation (Papaioannou & Ros-
sant, 1983).
An amphibian oocyte/early embryo ribonuclease named
ONCONASER* (ONC) (previously known as P-30 Protein),
a novel 12 kDa protein isolated from Rana pipiens eggs and
early embryos (Ardelt et al., 1991), appears to represent the
first instance of a successful isolation, purification and char-
acterization of the oocytic/early embryonic factor which is
capable of controlling tumour cell growth. This protein,
therefore, could be the molecular equivalent of at least part
of the biological anti-tumour cell growth activities of the
early embryonic tissues.
ONC has been reported to demonstrate anti-proliferative
and cytotoxic activity against several human tumour cell lines
in vitro (Darzynkiewicz et al., 1988), and has also been shown
to have a striking anti-tumour activity in vivo against the
M109 Madison lung carcinoma in mice (Mikulski et al.,
1990a). Currently, ONC is in the Phase II human clinical
trials and its activity is being assessed against a variety of
human solid tumours.
When tested in vitro against human ASPC-1 pancreatic
and A-549 lung adenocarcinoma cell lines, ONC interacted
synergistically with tamoxifen and trifluoperazine, respec-
tively (Mikulski et al., 1990b). One of the possible mechan-
isms of action of tamoxifen and phenothiazine derivatives is
an interference with a signal transduction involving cal-
modulin/Ca+2 and protein kinase C systems, and possibly an
anti-oestrogen binding site/intracellular histamine receptor,
resulting in an inhibition of the cell cycle progression (Mori
et al., 1980; Gulino et al., 1986; Brandes et al., 1987). Thus,
the observed synergistic effects could be related to the effects
of these drugs on the intracellular signal transduction path-
ways.
Guanosine triphosphate (GTP)-binding proteins (G-
proteins), whether heterotrimeric or monomeric such as pro-
ducts of ras, rho, R-ras, or rab genes (Gilman, 1987; Finegold
et al., 1990), all require to be anchored via farnesylated
carboxyl-terminal cysteine to the inner surface of the plasma
membrane, in order to be active in signal transduction path-
ways (Finegold et al., 1990; Barbacid, 1987; Madaule & Axel,
1985; Chardin & Tavitian, 1986; Lowe et al., 1987; Touchot
et al., 1987; Neer & Clapham, 1988; Schafer et al., 1989). The
15-carbon farnesyl group is attached post-translationally to
the sulfur of the carboxyl-terminal cysteine residue (Madaule
& Axel, 1985; Schafer et al., 1989; Casey et al., 1989). The
gamma subunits of heterotrimeric G-proteins (Finegold et
al., 1990) and nuclear lamins (Farnsworth et al., 1989; Vor-
burger et al., 1989) are also farnesylated, and in the case of
lamin B, the terminal cysteine (after farnesylation) is
carboxyl-methylated, in a cell cycle-dependent manner (Farns-
worth et al., 1989; Chelsky et al., 1987). The farnesylation
process is inhibited by LVT (Repko & Maltese, 1989), an
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase. It was also observed that LVT suppresses
cell proliferation by arresting cells in GI phase of the cell
cycle (Jakobisiak et al., 1991). It is likely, therefore, that the
anti-proliferative effect of LVT is the consequence of the
impairment of the signal transduction by this drug. Similar
inhibition of cell proliferation has been previously observed
with other HMG-CoA reductase inhibitors (Quesney-
Huneeus et al., 1979; Sinensky & Logel, 1985; Doyle &
Kandutsch, 1988).
These observations prompted us to study the possibility of
synergistic interactions between ONC and LVT. LVT was
presently investigated in both the lactone and beta-hydroxy
acid forms. The human tumour cell lines selected to this
study showed, in the pilot experiments, relative resistance to
each of these drugs when tested individually. This approach
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was expected to enhance the sensitivity for detection of the
possible synergism.
Materials and methods
Cell lines
The HT-520 squamous cell lung carcinoma line was obtained
from the National Cancer Institute, Frederick Cancer
Research Facility, Frederick, MD, with kind permission of
Dr J. Minna. These cells were grown in RPMI 1640 media
supplemented with 20% foetal bovine serum, 1% glutamine
and 1% Pen-Strep Fungizone (all agents obtained from JRH
Biosciences, Lenexa, KS). The cell number used in the MTT
assay was 2,000 cells/well. The ASPC-1 pancreatic and A-549
lung adenocarcinoma cell lines were obtained from the
American Type Culture Collection and were cultured as de-
scribed previously (Mikulski et al., 1990b).
The determination of cell number, description of the MTT
colorimetric assay, and statistical analysis were as previously
published (Mikulski et al., 1990b), except for drugs.
Since the specific role of the ras gene activation (mutation)
in tumour cell growth promotion, as compared to the nor-
mally expressed gene, remains unclear (see Discussion), and
only some human tumour cells express such mutated ras
genes, we did not feel that determining ras gene activation
status would be relevant in clarifying the drug interactions
observed in our study.
Drugs
ONCONASE (ONC) (P-30 Protein) supplied by Alfacell Cor-
poration, Bloomfield, NJ, was dissolved as previously de-
scribed (Mikulski et al., 1990b). Lovastatin (LVT),
Mr 404.55, was obtained from Merck, Sharp & Dohme (Rah-
way, NJ) as a lactone. 1.21 mg of LVT lactone was dissolved
in 3 ml of 100% ethanol to make a 1 mM stock solution. The
LVT lactone was activated in vitro according to the
previously published method (DeClue et al., 1991).
Mevalonate, as a mevalonic acid lactone (MVA) (Sigma
Chemical Co., St Louis, MO) was dissolved in ethanol and
then diluted with RPMI 1640 medium to make a 20 mM
stock solution.
Table I ONCONASE and lovastatin,
percentage inhibition of cell growth;
Clonogenicity studies
Clonogenicity studies were performed using 1,000 ASPC-1
cells plated/35 mm dish (Corning), and 100 A-549 cells
plated/35 mm dish. ONC and LVT lactone were added 24 h
after the cells had been plated. After six additional days of
culture, cells were harvested by fixation with methanol and
stained with Giemsa reagent, 1:20 dilution (Sigma Chemical
Co.). Any grouping of cells containing 30 cells or more was
counted as colony.
Flow cytometry
The A-549 cells were stained with combination of 4',6'-
diamidino-2-phenylindole (DAPI) and sulforhodamine 101,
as described before (Bruno et al., 1991). The cell fluorescence
was measured with the ICP-22A flow cytometer using the
UG-1 excitation filter and a combination of optical filters
and dichroic mirrors transmitting between 450 and 520 nm
(DAPI), and above 640 nm (sulforhodamine). The Phoenix
Flow Systems (San Diego, CA) software package was used
for data accumulation, and the Multicycle software for cell
cycle analysis (Bruno et al., 1991).
Cytotoxicity assessment
ASPC-1 (200 cells/well), and A-549 (30 cells/well) were plated
in Falcon 24-well plates and allowed to attach overnight. Six
plates were prepared per cell line, four groups per plate: (1)
untreated - medium only; (2) ONC, final concentration
1 jig ml-'; (3) LVT (lactone), final concentration 5pM (A-549)
or 7.5gM (ASPC-1); (4) ONC + LVT (at the same concentra-
tions). Trypan blue was added at 24, 48, 72, 96, 120 and
144h, and the cytotoxicity assessed in triplicates for each
data point.
Results
The cell growth inhibitory/cytotoxic activity of ONC alone,
and in combination with the acid and lactone forms of LVT,
were tested in three human tumour cell lines: ASPC-1 pan-
creatic carcinoma, A-549 lung adenocarcinoma, and HT-520
squamous cell lung carcinoma. Results are shown in Tables
I-III; the data represent mean percentage of inhibition of
alone and in combination. Mean
and ED50 values in MTT assay*
ONCC conc. ASPC-1 cells
(figml-') 0 0.1 1.0 10.0 ED50
ONC alone 0 19.7 12.6 76.4 7.561
(0.0)b (7.6) (5.2) (2.4) (7.48)
ONC + I5LC 12.4 25.7(S)d 59.8(S) 99.4(S) 0.282
(7.2) (5.0) (1.6) (1.0) (0.08)
ONC + l5aLc 13.8 31.3(S) 61.4(S) 99.3(S) 0.267
(1.6) (4.6) (3.8) (0.4) (0.02)
ONC + 25L 54.0 65.7(S) 91.8(S) 99.7(S) 0.034
(7.4) (7.6) (7.6) (0.4) (0.02)
ONC + 25aL 16.4 47.7(S) 82.1(S) 100.0(S) 0.114
(7.4) (5.2) (12.2) (0.0) (0.02)
ONC + 37L 47.6 77.1(S) 96.5(S) 100.0(S) 0.027
(5.8) (3.8) (2.8) (0.0) (0.00)
ONC + 37aL 31.5 52.0(S) 82.1(S) 99.8(S) 0.082
(3.8) (5.0) (1.6) (0.2) (0.02)
MTT colorimetric anti-proliferative/cytotoxic 7-day assay (24 h pre-
incubation of cells for anchorage, followed by 144 h drug(s) treatment time)
measures viability ofproliferating cells. Using Newman-Keuls statistical analysis
of significance, there was a significant (P value in the range of 0.01 to 0.001)
difference in mean % growth inhibition between ONC alone and ONC in
combinations, across varying concentrations of ONC; IONC = ONCONASE;
bNumbers in parentheses represent standard deviations; C15gm lovastatin
lactone; dS = Synergism, i.e., the Interaction Index, defined as the sum of the
ratios of the equi-effective (EDm) doses of ONC used in combination with
respective form and concentration of LVT and used alone, and of the
equi-effective (EDm) doses of LVT used in combination with ONC and used
alone, was less than 1.0; C15 JM lovastatin activated in vitro.306 S. MIKULSKI et al.
Table II ONCONASE and lovastatin, alone and in combination. Mean
percentage inhibition of cell growth and ED50 values in MTT assay
ONC" conc. A-549 cells
(Ltgml-,) 0 0.1 1.0 10.0 ED50
ONC alone 0 8.7 2.0 74.6 20.255
(0.0)b (19.2) (3.8) (1.6) (5.36)
ONC + 15LC 17.3 19.3(A)d 26.3(A) 78.8(S)e 2.903
(6.4) (4.2) (7.2) (2.4) (1.16)
ONC + 15aL1 26.6 30.1(S) 37.1(S) 85.6(S) 0.988
(2.2) (2.4) (3.6) (0.6) (0.18)
ONC + 25L 46.3 49.2(S) 61.4(S) 89.0(S) 0.127
(6.2) (6.4) (3.6) (1.8) (0.06)
ONC + 25aL 36.2 39.7(S) 45.3(S) 86.0(S) 0.381
(3.2) (6.8) (3.2) (0.6) (0.16)
ONC + 37L 89.0 87.8(S) 88.1(S) 89.2(S) <0.001
(2.8) (3.0) (2.6) (2.4) -
ONC + 37aL 48.4 56.9(S) 64.7(S) 89.0(S) 0.048
(6.2) (1.2) (3.2) (3.0) (0.00)
Using Newman-Keuls statistical analysis, there was a significant (P value in
the range of 0.01 to 0.001) difference in mean % growth inhibition between
ONC alone and ONC in combinations, across varying concentrations of ONC;
'ONC = ONCONASE; bNumbers in parentheses represent standard deviations; C15gM lovastatin lactone; dA = Antagonism, i.e., Interaction Index above 1.0;
eS = Synergism, i.e., Interaction Index below 1.0; 1l5JAM lovastatin activated in
vitro.
Table III ONCONASE and lovastatin, alone and in combination. Mean
percentage inhibition of cell growth and ED^, values in MTT assay
ONCi conc. HT-520 cells
(jigml-]) 0 0.1 1.0 10.0 ED50
ONC alone 0 7.8 45.9 88.2 1.143
(0.0)b (0.1) (6.4) (0.4) (0.16)
ONC + 15LC 53.5 50.8(S)d 75.0(S) 89.7(S) 0.054
(3.3) (2.1) (1.8) (1.1) (0.00)
ONC + l5aLe 69.6 70.6(A)f 83.2(S) 90.5(S) 0.001
(5.4) (3.7) (0.4) (0.8) (0.00)
ONC + 25L 67.4 70.4(S) 81.0(S) 91.3(S) 0.001
(0.4) (2.1) (0.3) (0.6) (0.00)
ONC + 25aL 71.1 73.5(A) 85.5(S) 92.1(S) 0.001
(3.0) (2.8) (0.1) (0.8) (0.00)
ONC + 37L 77.2 82.7(S) 87.2(S) 90.2(S) <0.001
(5.2) (1.6) (0.8) (0.1) _
ONC + 37aL 79.0 78.5(S) 88.3 92.4(S) <0.001
(3.7) (1.1) (0.6) (0.1) _
Using Newman-Keuls statistical analysis, there was a significant (P value in
the range of 0.01 to 0.001) difference in mean % growth inhibition of cell
growth between ONC alone and ONC in combinations at the 0.1 fgml-' and
1.0Ag mlh of ONC, but not significant at the 10.0 igml' of ONC - at this
highest concentration ONC was very effective alone (88.2% inhibition);
'ONC = ONCONASE; bNumbers in parentheses represent standard deviations; C15JAM lovastatin lactone; dS = Synergism, i.e., the Interaction Index below 1.0;
115JM lovastatin activated in vitro; 'A = Antagonism, i.e., the Interaction Index
above 1.0.
tumour cell growth as compared with untreated control, with
Newman-Keuls statistical analyses of significance comparing
various treatment groups and expressed as P values (see
footnotes to Tables I-III).
The equi-effective doses, i.e., ED50 values, were calculated
for ONC alone, LVT beta-hydroxy acid and lactone alone,
and for the combinations of ONC with both forms of LVT.
In order to determine the type of interactions between
different agents used in combinations, the interactions index
has been used (Berenbaum, 1981) according to the following
formula for no interaction:
A, + Bc = 1.0
Aa Ba
where A, and Bc represent an equi-effective dose (e.g., ED5,
value = 50% of decrease of cell viability as compared with
the untreated control) of each of the interactive drugs in
combination, and Aa and Ba represent the same equi-effective
dose of each drug used alone. The index value above 1.0
represents antagonism, and below 1.0 synergism (Berenbaum,
1981).
Tables I, II and III present mean percentages of growth
inhibition whereby varying doses of ONC were used either
alone or in combination with various doses of both forms of
LVT in ASPC-1, A-549 and HT-520 cells, respectively. The
concentrations of LVT were selected based on our previous
titration experiments to choose suboptimal doses, appropri-
ate for detecting drug interactions. The mean values were
derived from quadruplicate tests for each data point.
The interactions between ONC and both forms of LVT
were clearly synergistic, as defined by Berenbaum (1981),
across varying concentrations ofONC, and designated by the
capital letter 'S' in parentheses; letter 'A' designates an
antagonism.
As can also be seen in Tables I-III, in all of the three cell
lines the increased tumour cell growth inhibitory activities of
the combination of ONC with both the beta-hydroxy acid
and the lactone forms of LVT, when compared with ONCAMPHIBIAN OOCYTE RNASE/LOVASTATIN INTERACTIONS 307
alone, were highly significantly different, with P values of
0.001 across varying concentrations of ONC. These results
were reproducible in repeated experiments. Also, at certain
concentrations of both forms of LVT, the activity of the
combination of ONC with LVT-lactone was at least equal to
that using the beta-hydroxy acid form of this drug. In fact, at
the highest concentration of LVT used in ASPC-1 and A-549
lines, the activity of the combination of ONC with the lac-
tone form of LVT was significantly greater than that with the
acid form. These findings were observed consistently in
repeated experiments.
Clonogenicity studies of ASPC-1 and A-549 cells
confirmed the MTT assay-demonstrable synergistic interac-
tion betwen ONC and LVT (Table IV). Using trypan blue
dye exclusion test in continuous cell culture over 144 h, it
was clearly shown that the synergistic interaction manifested
itself not only as a potentiated cytostatic effect, but also as
an increased cytotoxic activity, which was time-dependent
(Figure 1).
Figure 2 shows cell cyle distribution of A-549 cells treated
with ONC alone, lactone form of LVT alone, and the com-
bination of both drugs. ONC alone (Figure 2b) at 1 sg ml-'
slightly increased the proportion ofcells in G2/M phase, LVT
alone at 5jM significantly decreased the proportion ofcells in
S phase from 33% to 13%, but had no effect at lower
(2.5pM) concentration. Combination of both drugs (Figures
2fand 2g) resulted in a lowering of the proportion of S phase
cells but to a lesser degree compared to 5SlM LVT alone. The
proportion of GI cells, however, is higher in the cultures
treated with ONC + LVT than in the absence of these drugs.
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When these data are compared to growth curves, the latter
indicating a very significant (several-fold) slow-down of cell
proliferation, it is evident that the suppression of cell growth
by combination of ONC and LVT is a result of the prolonga-
tion of the overall cell cycle, rather than the specific arrest in
particular phase of the cycle. GI phase, however, is more
Table IV Clonogenicity of ASPC-1 and A-549 cells treated with
ONCONASE and lovastatin, alone and in combination
Mean numbr of colonies
formed (+/- S.D.)
Treatment group ASPC-1 A-549
CTL 57 (4.9) 52 (4.2)
LVT 7.5jiM alone 23 (7.1) 9 (1.4)-
ONC 0.2 iLg ml-I alone 51 (4.2) 38 (7.8)
ONC 2.5jigml-' alone 31 (6.4) 28 (12.0)
ONC 5.0jigml-' alone 21 (0.7) 10 (3.5)
LVT 7.5jiM+ ONC 0.2 g ml-' 25 (3.5) 0 (O)a
LVT 7.5 liM+ONC 2.5 jigml- 7 (2.1) 0 (O)a
LVT 7.5gM+ONC 5.0 ggml-' 3 (1.4) 0 (0)a
S.D. = standard deviations; CTL = untreated controls, ASPC-1
1,000 cells plated/dish, and A-549 100 cells plated/dish, under the
conditions specified in the Materials and methods; LVT = lovastatin
lactone; ONC = ONCONASE. aIn the A-549 cell system, lovastatin
was also used at the 5giM concentration, i.e., the same concentration
as used in both the trypan blue dye exclusion and flow cytometry
studies, and the mean numbers of colonies (with standard deviations
in parentheses) were vertically 21 (3.5) for LVT alone, and 0 (0) for
all combinations of LVT 5jiM with varying concentrations of ONC.
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Figure 1 Trypan blue dye exclusion cell viability assessments in the two human tumour cell lines, expressed as: a, the natural
logarithm of an absolute number of viable ASPC-1 cells (abscissa) in time (ordinate); b, a time-dependent percentage of dead cells
in the ASPC-1 cell system; c, the natural logarithm of an absolute number of viable A-549 cells (abscissa) in time (ordinate), and d,
a time-dependent percentage of dead cells in the A-549 cell system. Symbols: 0-0-0 represents untreated controls; *-0-0
represents ONCONASE at 1 jg ml-' alone; 0-0-0 represents Lovastatin at 7.5 jiM concentration in ASPC-1 cells, and at 5 jiM
in A-549 cells, alone A-A-A represents a combination of both agents at the same concentrations, respectively. All cells were
treated as described in the Material and methods section. The plotted points represent means of three values with standard
deviations.
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Figure 2 DNA frequency distribution histograms of A-549 cells untreated and treated with ONC and LVT: a, untreated controls;
b, cells treated with ONC alone at final concentration of 1 jig ml- l for 72 h; c, cells treated with ONC alone at final concentration
of 0.5 jig ml-' for 72 h; d, cells treated with 5 jM LVT alone for 72 h; e, cells treated with 2.5 jiM LVT alone for 72 h; f, cells
treated with the combination of ONC at 1 jlg ml- and 5 giM LVT for 72 h; g, cells treated with the combination of ONC at
0.5 jig ml-' and 2.5 jM LVT for 72 h. Percentages of cells in different phases of the cell cycle are given in each panel.
prolonged than the remaining portion of the cycle. This is in
contrast to the LVT alone at 5jM which arrests cells quite
specifically in G, phase.
While the cytostatic effects of the combined treatment with
ONC and LVT are manifested early during the treatment (no
cell death but significant inhibition of cell growth were seen
during the first 72 h of treatment with 1 jig ml- 1 of ONC + 5
or 7.5jiM of LVT), the cytotoxic effects became apparent, and
progressively increased, later (Figure 1).
To confirm the primary mechanism of action of LVT,
HT-520 cells were subjected to both the acid and the lactone
forms of LVT, with and without concomitant 200gM
mevalonic acid lactone (MVA) (Jakobisiak et al., 1991).
MVA partially reversed both the LVT-induced cell growth
inhibition and the interactive capability of LVT; these results
are presented in Table V and expressed as ED50 values for
the ONC + LVT combination in the MTT assay.
Discussion
Our present results show that the combinations of ONC with
both acid and lactone forms of LVT demonstrate a synergis-
tic anti-proliferative activity, as measured by the MTT col-
orimetric assay, clonogenicity studies and the trypan blue dye
exclusion assessments. The flow cytometric studies indicated
that the cytostatic effect induced by treatment with LVT +
ONC results predominantly from the extension of duration
of all phases of the cell cycle. GI phase, however, appears to
be more prolonged than S and G2/M by ONC + LVT com-
bination, compared to the untreated cells. Interstingly,
whereas LVT alone at 5gM concentration produced the GI
cell arrest, the addition of ONC partially abolished the Gl-
specific effect of LVT, presumably by entrapping the cells in
other phases of the cell cycle.
We have also demonstrated that these activites of LVT
alone and in combination are reversible by MVA, thus
confirming a primary mechanism of action of LVT as an
inhibitor of HMG-CoA reductase. The findings of at least
equal degree of anti-tumour activitiy exerted by LVT lactone
suggest that this form of LVT can be activated by tumour
cells, and that the in vitro activation of LVT lactone may not
always be necessary. These findings have very important
practical applications with regard to the potential use of LVT
in in vivo systemic cancer treatment.
The ability of MVA, but not cholesterol, to reverse the
HMG-CoA reductase inhibitor-induced cell growth arrest
and DNA synthesis inhibition (Quesney-Huneeus et al.,
1979), as well as a direct stimulation of DNA synthesis in
mouse fibroblasts upon microinjection of recombinant p21
ras proteins (Stacey & Kung, 1984), and the GI phase arrest
of growing cells and the reversal of a transformed phenotype
induced by microinjection of monoclonal anti-p21 antibodies
Table V HT-520 cell growth inhibition induced by ONCONASE
alone or in combination with lovastatin and the reversal ofinhibition
by mevalonate, expressed as ED5o values in MTT assay with
standard deviations
Treatment group ED50 S.D.
ONC alone 1.143 (0.16)
ONC+ 200juM MVA 0.632 (0.16)
ONC + l5aLVT 0.001 (0.00)
ONC + 15LVT 0.054 (0.01)
ONC + 15aLVT + 200jiM MVA 0.233 (0.07)
ONC+15LVT + 200 jM MVA 0.221 (0.03)
ONC = ONCONASE; MVA = mevalonate; 15aLVT = 15giM in
vitro activated lovastatin, i.e., beta-hydroxy acid form;
15LVT = 15jIM lovastatin lactone. The 15I1M LVT lactone alone
caused a mean 53.5% inhibition of tumour cell growth, which was
decreased to a mean 19.8% at 200 gM MVA. The 15 IM aLVT alone
caused a mean 69.5% inhibition of tumour cell growth, which was
decreased to a mean 24.1% at 200 jiM MVA. 200gM MVA alone
caused 9.9% inhibition of cell growth. Therefore, 200jiM MVA
reversed the cell growth inhibition induced by LVT lactone by
62.9%, and that induced by aLVT by 65%. In fact, since 200 jiM
MVA alone was inhibitory to the cell growth, as also reflected by
ED50 value for ONC + MVA combination being lower than that of
ONC alone, the actual reversals of cell growth inhibition have been
greater than was actually observed.
(Kung et al., 1986), all strongly suggest an essential cell
growth regulatory activity of the inner plasma membrane-
anchored p21 ras proteins. However, since LVT could
interfere with the function of over 40 other proteins known
to be normally isoprenylated (Madaule & Axel, 1985; Chardin
& Tavitian, 1986; Touchot et al., 1987; Casey et al., 1989;
Farnsworth et al., 1989; Schmidt et al., 1984), it is also
possible that the observed anti-proliferative activity of this
drug may be as well related to the interference with the
function of other than, or in addition to, p21 ras protein(s),
e.g., nuclear scaffold lamins (Farnsworth et al., 1989; Vor-
burger et al., 1989). These latter proteins undergo cell-cyclical
proteolytic degradation which is associated with a generation
of a 46 kD protein possessing a nucleoside triphosphatase
activity. This activity, in turn, is thought to participate in
nucleocytoplasmic transport of RNA (Tokes & Clawson,
1989). It has been previously demonstrated that, by analogy
to the factor a of Saccharomyces cerevisiae and p21 ras
proteins, the carboxyl-terminal cysteine of lamin B is
farnesylated and its carboxyl group methylated (Anderegg et
al., 1988; Farnsworth et al., 1989) and, interestingly, in a cell
cycle-dependent manner (Chelsky et al., 1987). All of these
findings emphasise our lack of knowledge of a precise
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The observed synergism between ONC and LVT might be
related to their effects on RNA metabolism: ONC through its
ribonucleotyic activity (Ardelt et al., 1991) capable of de-
stroying specific species of RNA, and LVT acting via inter-
ference with the lamin proteins-related nucleocytoplasmic
RNA transport (Tokes & Clawson, 1989). Both actions could
conceivably inhibit cell growth.
An increased expression of a mutated ('activated') ras gene
product(s) has been observed in a variety of human malig-
nancies, including adenocarcinoma of the lung (Rodenhuis et
al., 1987), pre-malignant and high grade lesions of bladder
carcinoma (Viola et al., 1985), colon carcinoma (Forrester et
al., 1987), acute myeloid leukaemia (Bos et al., 1985), ovarian
serous cystadenocarcinoma (Feig et al., 1984), and melanoma
(Albino et al., 1984). Using monoclonal antibodies specific
for synthetic eight residues peptide containing amino acids
corresponding to positions 10-17 of the mutated in positon
12 Ha-ras gene product (valine substituted for glycine), it was
shown that mutated ras gene expression is markedly in-
creased in most of the human colon and mammary car-
cinomas, but not in normal colonic and mammary epithelia,
nor benign fibroadenoma and/or fibrocystic disease (Hand et
al., 1984).
Although an increased expression of normal (not mutated)
human Ha-ras proto-oncogene has been shown to be capable
of inducing tumourigenic transformation of mammalian cells
(Chang et al., 1982), such an enhanced expression appears to
be infrequent in human neoplasia, with an approximate
incidence of 1% (Barbacid, 1987), and in some instances it
may only induce immortalisation ofcells (Spandidos & Wilkie,
1984).
In majority of human tumours, the 'activation' (mutation)
of ras genes did not seem to correlate with the histo-
pathological properties of the tumour, and was not
associated with any specific type of neoplasia (Barbacid,
1987; Forrester et al., 1987). The 'activated' ras genes were
detectable ony in some, but not other, tumour deposits of
human metastatic melanoma isolated from the same patient,
thus reflecting a significant tumour cell heterogeneity with
regard to ras genes' expression (Albino et al., 1984).
Although the activated ras genes may not be able to induce
malignant transformation by themselves, they can be effective
as co-inducers of such transformation in cooperation with,
e.g., nuclear oncogenes such as c-myc (Land et al., 1983;
Weinberg, 1989). All ofthese findings point to the still poorly
understood relative clinical importance of both normally ex-
pressed and mutated ras gene products.
The observed synergism between ONC (currently being
evaluated in Phase II human clinical trials) and LVT (which
has been used in the treatment of certain forms of hyper-
cholesterolemia), as reflected by both the increased cytostatic
and cytotoxic effects, suggests that this combination should
be investigated in vivo, including human trials. It may offer a
new therapeutic approach against notoriously resistant
human solid tumours.
The authors would like to thank Najma Khalid for excellent help in
preparing the figures and tables.
Z.D. was supported in part by NCI grant R37 CA23296.
References
ALBINO, A.P., LESTRANGE, R., OLIFF, A.I., FURTH, M.E. & OLD, L.J.
(1984). Transforming ras genes from human melanoma: a
manifestation of tumour heterogeneity? Nature, 308, 69-72.
ANDEREGG, R.J., BETZ, R., CARR, S.A., CRABB, J.W. & DUNTZE, W.
(1988). Structure of Saccharomyces cerevisiae mating hormone
a-factor. Identification of S-farnesyl cysteine as a structural com-
ponent. J. Biol. Chem., 263, 18236-18240.
ARDELT, W., MIKULSKI, S.M. & SHOGEN, K. (1991). Amino acid
sequence of an anti-tumor protein from Ranapipiens oocytes and
early embryos. Homology to pancreatic ribonucleases. J. Biol.
Chem., 266, 245-251.
BARBACID, M. (1987). ras genes. Ann. Rev. Biochem., 56, 779-827.
BERENBAUM, M.C. (1981). Criteria for analysing interactions
between biologically active agents. Adv. Cancer Res., 35,
269-335.
BOS, J.L., TOKSOZ, D., MARSHALL, C.J., VERLAAN-DE VRIES, M.,
VEENEMAN, G.H., VAN DER EB, A.J., VAN BOOM, J.H., JANSSEN,
J.W.G. & STEENVOORDEN, A.C.M. (1985). Amino acid substitu-
tions at codon 13 of the N-ras oncogene in human acute myeloid
leukaemia. Nature, 315, 726-730.
BRANDES, L.J., BOGDANOVIC, R.P., CAWKER, M.D. & LABELLA,
F.S. (1987). Histamine and growth: interactions of antiestrogen
binding site ligands with a novel histamine site that may be
associated with calcium channels. Cancer Res., 47, 4025-4031.
BRUNO, S., CRISSMAN, H.A., BAUER, K.D. & DARZYNKIEWICZ, Z.
(1991). Changes in cell nuclei during S phase: progressive
chromatin condensation and altered expression of the prolifer-
ation-associated nuclear proteins Ki-67, cyclin (PCNA), p105,
and p34. Exp. Cell. Res., 196, 99-106.
CASEY, P.J., SOLSKI, P.A., DER, C.J. & BUSS, J.E. (1989). p2lras is
modified by a farnesyl isoprenoid. Proc. Natl Acad. Sci. USA, 86,
8323-8327.
CHANG, E.H., FURTH, M.E., SCOLNICK, E.M. & LOWY, D.R. (1982).
Tumorigenic transformation of mammalian cells induced by a
normal human gene homologous to the oncogene of Harvey
murine sarcoma virus. Nature, 297, 479-483.
CHARDIN, P. & TAVITIAN, A. (1986). The ral gene: a new ras
related gene isolated by the use ofa synthetic probe. EMBO J., 5,
2203-2208.
CHELSKY, D., OLSON, J.F. & KOSHLAND, D.E. Jr (1987). Cell cycle-
dependent methyl esterification of lamin B. J. Biol. Chem., 262,
4304-4309.
DARZYNKIEWICZ, Z., CARTER, S.P., MIKULSKI, S.M., ARDELT, W.J.
& SHOGEN, K. (1988). Cytostatic and cytotoxic effects of Pannon
(P-30 Protein), a novel anticancer agent. Cell Tissue Kinet., 21,
169-182.
DECLUE, J.E., VASS, W.C., PAPAGEORGE, A.G., LOWY, D.R. & WIL-
LUMSEN, B.M. (1991). Inhibition of cell growth by lovastatin is
independent of ras function. Cancer Res., 51, 712-717.
DOYLE, J.W. & KANDUTSCH, A.A. (1988). Requirement for mevalo-
nate in cycling cells: quantitative and temporal aspects. J. Cell.
Physiol., 137, 133-140.
FARNSWORTH, C.C., WOLDA, S.L., GELB, M.H. & GLOMSET, J.A.
(1989). Human lamin B contains a farnesylated cysteine residue.
J. Biol. Chem., 264, 20422-20429.
FEIG, L.A., BAST, R.C. Jr, KNAPP, R.C. & COOPER, G.M. (1984).
Somatic activation of ras' gene in a human ovarian carcinoma.
Science, 223, 698-701.
FINEGOLD, A.A., SCHAFER, W.R., RINE, J., WHITEWAY, M. &
TAMANOI, F. (1990). Common modifications of trimeric G pro-
teins and ras protein: involvement of polyisoprenylation. Science,
249, 165-169.
FORRESTER, K., ALMOGUERA, C., HAN, K., GRIZZLE, W.E. &
PERUCHO, M. (1987). Detection of high incidence of K-ras onco-
genes during human colon tumorigenesis. Nature, 327, 298-303.
GILMAN, A.G. (1987). G proteins: transducers of receptor-generated
signals. Ann. Rev. Biochem., 56, 615-649.
GULINO, A., BARRERA, G., VACCA, A., FARINA, A., FERRETTI, C.,
SCREPANTI, I., DIANZANI, M.U. & FRATI, L. (1986). Calmodulin
antagonism and growth-inhibiting activity of triphenyl-ethylene
antiestrogens in MCF-7 human breast cancer cells. Cancer Res.,
46, 6274-6278.
HAND, P.H., THOR, A., WUNDERLICH, D., MURARO, R., CARUSO,
A. & SCHLOM, J. (1984). Monoclonal antibodies of predefined
specificity detect activated ras gene expression in human mam-
mary and colon carcinomas. Proc. Natl Acad. Sci. USA, 81, 5227-5231.
JAKOBISIAK, M., BRUNO, S., SKIERSKI, J. & DARZYNKIEWICZ, Z.
(1991). Cell cycle-specific effects of lovastatin. Proc. Natl Acad.
Sci. USA, 88, 3628-3632.
KUNG, H.-F., SMITH, M.R., BEKESI, E., MANNE, V. & STACEY, D.W.
(1986). Reversal of transformed phenotype by monoclonal
antibodies against Ha-ras p21 proteins. Exp. Cell Res., 162,
363-371.310 S. MIKULSKI et al.
LAND, H., PARADA, L.F. & WEINBERG, R.A. (1983). Tumorigenic
conversion of primary embryo fibroblasts requires at least two
cooperating oncogenes. Nature, 304, 596-602.
LOWE, D.G., CAPON, D.J., DELWART, E., SAKAGUCHI, A.Y.,
NAYLOR, S.L. & GOEDDEL, D.V. (1987). Structure of the human
and murine R-ras genes, novel genes closely related to ras proto-
oncogenes. Cell, 48, 137-146.
MADAULE, P. & AXEL, R. (1985). A novel ras-related gene family.
Cell, 41, 31-40.
MIKULSKI, S.M., BERNSTEIN, E.H., ARDELT, W., SHOGEN, K. &
MENDUKE, H. (1990a). Striking increase of survival of mice
bearing M109 Madison carcinoma treated with a novel protein
from amphibian embryos. J. Natl Cancer Inst., 82, 151-153.
MIKULSKI, S.M., VIERA, A., ARDELT, W., MENDUKE, H. &
SHOGEN, K. (1990b). Tamoxifen and trifluoroperazine (Stelazine)
potentiate cytostatic/cytotoxic effects of P-30 Protein, a novel
protein possessing anti-tumour activity. Cell Tissue Kinet., 23,
237-246.
MINTZ, B. & ILLMENSEE, K. (1975). Normal genetically mosaic mice
produced from malignant teratocarcinoma cells. Proc. Natl Acad.
Sci. USA, 72, 3585-3589.
MORI, T., TAKAI, Y., MINAKUCHI, R., YU, B. & NISHIZUKA, Y.
(1980). Inhibitory action of chlorpromazine, dibucaine and other
phospholipid-interacting drugs on calcium-activated, phospho-
lipid-dependent protein kinase. J. Biol. Chem., 255, 8378-8380.
NEER, E.J. & CLAPHAM, D.E. (1988). Roles of G protein subunits in
transmembrane signalling. Nature, 333, 129-134.
PAPAIOANNOU, V.E., MCBURNEY, M.W., GARDNER, R.L. & EVANS,
M.J. (1975). Fate of teratocarcinoma cells injected into early
mouse embryos. Nature, 258, 70-73.
PAPAIOANNOU, V.E. & ROSSANT, J. (1983). Effects of the embryonic
environment on proliferation and differentiation of embryonal
carcinoma cells. Cancer Surv., 2, 165-183.
QUESNEY-HUNEEUS, V., WILEY, M.H. & SIPERSTEIN, M.D. (1979).
Essential role for mevalonate synthesis in DNA replication. Proc.
Natl Acad. Sci. USA, 76, 5056-5060.
REPKO, E.M. & MALTESE, W.A. (1989). Post-translational isoprenyla-
tion of cellular proteins is altered in response to mevalonate
availability. J. Biol. Chem., 264, 9945-9952.
RODENHUIS, S., VAN DE WETERING, M.L., MOOI, W.J., EVERS, S.G.,
VAN ZANDWIJK, N. & BOS, J.L. (1987). Mutational activation of
the K-RAS oncogene. A possible pathogenetic factor in
adenocarcinoma of the lung. N. Engl. J. Med., 317, 929-935.
SCHAFER, W.R., KIM, R., STERNE, R., THORNER, J., KIM, S.-H. &
RINE, J. (1989). Genetic and pharmacological suppression of
oncogenic mutations in RAS genes of yeast and humans. Science,
245, 379-385.
SCHMIDT, R.A., SCHNEIDER, C.J. & GLOMSET, J.A. (1984). Evidence
of posttranslational incorporation of a product of mevalonic acid
into Swiss 3T3 cell proteins. J. Biol. Chem., 259, 10175-10180.
SINENSKY, M. & LOGEL, J. (1985). Defective macromolecule biosyn-
thesis and cell-cycle progression in a mammalian cell starved for
mevalonate. Proc. Natl Acad. Sci. USA, 82, 3257-3261.
SPANDIDOS, D.A. & WILKIE, N.M. (1984). Malignant transformation
of early passage rodent cells by a single mutated human
oncogene. Nature, 310, 469-475.
STACEY, D.W. & KUNG, H.-F. (1984). Transformation of NIH 3T3
cells by microinjection of Ha-ras p21 protein. Nature, 310,
508-511.
TOKES, Z.A. & CLAWSON, G.A. (1989). Proteolytic activity associated
with the nuclear scaffold. The effect ofself-digestion on lamins. J.
Biol. Chem., 264, 15059-15065.
TOUCHOT, N., CHARDIN, P. & TAVITIAN, A. (1987). Four additional
members of the ras gene superfamily isolated by an oligonucleo-
tide strategy: molecular cloning of YPT-related cDNAs from a
rat brain library. Proc. Natl Acad. Sci. USA, 84, 8210-8214.
VIOLA, M.V., FROMOWITZ, F., ORAVEZ, S., DEB, S. & SCHLOM, J.
(1985). ras oncogene p21 expression is increased in premalignant
lesions and high grade bladder carcinoma. J. Exp. Med., 161,
1213-1218.
VORBURGER, K., KITTEN, G.T. & NIGG, E.A. (1989). Modification
of nuclear lamin proteins by a mevalonic acid occurs in reticulo-
cyte lysates and requires the cysteine residues of the C-terminal
CXXM motif. EMBO J., 8, 4007-4014.
WEINBERG, R.A. (1989). Oncogenes, antioncogenes, and the
molecular bases of multistep carcinogenesis. Cancer Res., 49,
3713-3721.